Breaking News
December 15, 2018 - Young people suffering chronic pain battle isolation and stigma as they struggle to forge their identities
December 15, 2018 - Lifespan extension at low temperatures depends on individual’s genes, study shows
December 15, 2018 - New ingestible capsule can be controlled using Bluetooth wireless technology
December 15, 2018 - Researchers uncover microRNAs involved in the control of social behavior
December 15, 2018 - Research offers hope for patients with serious bone marrow cancer
December 15, 2018 - Link between poverty and obesity is only about 30 years old, study shows
December 15, 2018 - Mass spectrometry throws light on old case of intentional heavy metal poisoning
December 15, 2018 - BeyondSpring Announces Phase 3 Study 105 of its Lead Asset Plinabulin for Chemotherapy-Induced Neutropenia Meets Primary Endpoint at Interim Analysis
December 15, 2018 - Study finds that in treating obesity, one size does not fit all
December 15, 2018 - Tenacity and flexibility help maintain psychological well-being, mobility in older people
December 15, 2018 - Study reveals role of brain mechanism in memory recall
December 15, 2018 - High levels of oxygen encourage the brain to remain in deep, restorative sleep
December 15, 2018 - Experimental HIV vaccine strategy works in non-human primates, research shows
December 15, 2018 - Genetically modified pigs could limit replication of classical swine fever virus, study shows
December 15, 2018 - FDA Approves Herzuma (trastuzumab-pkrb), a Biosimilar to Herceptin
December 15, 2018 - Cost and weight-loss potential matter most to bariatric surgery patients
December 15, 2018 - Cancer Research UK and AstraZeneca open new Functional Genomics Centre
December 15, 2018 - New research lays out potential path for treatment of Huntington’s disease
December 15, 2018 - Prestigious R&D 100 Award presented to Leica Microsystems
December 15, 2018 - Study shows septin proteins detect and kill gut pathogen, Shigella
December 15, 2018 - Study sheds new light on disease-spreading mosquitoes
December 15, 2018 - 2017 Saw Slowing in National Health Care Spending
December 15, 2018 - Monitoring movement reflects efficacy of mandibular splint
December 15, 2018 - Study supports BMI as useful tool for assessing obesity and health
December 15, 2018 - Self-guided, internet-based therapy platforms effectively reduce depression
December 15, 2018 - Organically farmed food has bigger climate impact than conventional food production
December 15, 2018 - Faster, cheaper test has potential to enhance prostate cancer evaluation
December 15, 2018 - Researchers study abnormal blood glucose levels of patients after hospital discharge
December 15, 2018 - Swedish scientists explore direct association of dementia and ischemic stroke deaths
December 15, 2018 - Study finds 117% increase in number of dementia sufferers in 26 years
December 15, 2018 - Eczema Can Drive People to Thoughts of Suicide: Study
December 15, 2018 - Link between neonatal vitamin D deficiency and schizophrenia confirmed
December 15, 2018 - Nurse denied life insurance because she carries naloxone
December 15, 2018 - Ritalin drug affects organization of pathways that build brain networks used in attention, learning
December 15, 2018 - Research pinpoints two proteins involved in creation of stem cells
December 15, 2018 - Gut bacteria may modify effectiveness of anti-diabetes drugs
December 15, 2018 - Early physical therapy associated with reduction in opioid use
December 15, 2018 - Breast cancer protection from pregnancy begins many decades later, study finds
December 15, 2018 - How often pregnant women follow food avoidance strategy to prevent allergy in offspring?
December 15, 2018 - Using machine learning to predict risk of developing life-threatening infections
December 15, 2018 - How imaginary friends could boost children’s development
December 15, 2018 - Folate deficiency creates more damaging chromosomal abnormalities than previously known
December 15, 2018 - Study provides new insights into molecular mechanisms underlying role of amyloid in Alzheimer’s disease
December 15, 2018 - For the asking, a check is in the mail to help pay for costly drugs
December 15, 2018 - UA scientists uncover biological processes leading to rare brain disorder in babies
December 15, 2018 - The largest database on industrial poisons
December 15, 2018 - ESMO Immuno-Oncology Congress showcases novel technologies set to benefit many cancer patients
December 15, 2018 - Ovid Therapeutics Announces Plans to Move into a Phase 3 Trial in Pediatric Patients Based on End-of-Phase 2 Meeting for OV101 in Angelman Syndrome
December 15, 2018 - Left ventricular noncompaction – Genetics Home Reference
December 15, 2018 - Children’s sleep not significantly affected by screen time, new study finds
December 15, 2018 - When should dementia patients stop driving? A new guidance for clinicians
December 15, 2018 - Researchers use INTEGRA’s VIAFLO 96/384 to streamline the experimental workflow
December 15, 2018 - Researchers discover protein involved in nematode stress response
December 15, 2018 - Cancer patients have greater risk of developing shingles, study shows
December 14, 2018 - UAlberta scientists identify biomarkers for detecting Alzheimer’s disease in saliva samples
December 14, 2018 - Study uncovers link between tube travel and spread of flu-like illnesses
December 14, 2018 - Caffeine plus another compound in coffee may fight Parkinson’s disease
December 14, 2018 - GW researchers review studies on treatments for prurigo nodularis
December 14, 2018 - Lack of peds preventive care ups unplanned hospital admissions
December 14, 2018 - Miscarriage: When Language Deepens Pain
December 14, 2018 - New method helps better understand pathological development of ALS
December 14, 2018 - Intellectually active lifestyle confers protection against neurodegeneration in Huntington’s patients
December 14, 2018 - Mammalian collagen nanofibrils become stronger and tougher with exercise
December 14, 2018 - Considerable Morbidity, Mortality Due to Animal Encounters
December 14, 2018 - Researchers find inhibiting one protein destroys toxic clumps seen in Parkinson’s disease
December 14, 2018 - How early physical therapy can lessen the long-term need for opioids
December 14, 2018 - Depression, suicide rates highest in Mountain West states
December 14, 2018 - New model could cure the potential to underestimate how quickly diseases spread
December 14, 2018 - Exercise-induced hormone activates cells critical for bone remodeling in mice
December 14, 2018 - Researchers discover new mechanism behind spread of malignant pleural mesothelioma
December 14, 2018 - Health Tip: Celebrate a Healthier Holiday
December 14, 2018 - Scalpel-free surgery enhances quality of life for Parkinson’s patients, study finds
December 14, 2018 - Early physical therapy can reduce risk, amount of long-term opioid use | News Center
December 14, 2018 - Genetic marker, predictor of early relapse in common childhood cancer discovered
December 14, 2018 - Study could lead to a potential new way of treating sepsis
December 14, 2018 - New protein complex helps embryonic stem cells to maintain their indefinite potential
December 14, 2018 - Salk professor receives $1.8 million from NOMIS Foundation for research on mechanisms to promote health
December 14, 2018 - New discovery will improve the safety and predictability of CRISPR
December 14, 2018 - Geneticists discover how sex-linked disorders arise
December 14, 2018 - New method to visualize small-molecule interactions inside cells
Triple Therapy Improves PFS in Certain Breast Ca Patients

Triple Therapy Improves PFS in Certain Breast Ca Patients

image_pdfDownload PDFimage_print

Action Points

  • Dual human epidermal growth factor receptor 2 (HER2) blockade with lapatinib (Tykerb) and trastuzumab (Herceptin) + an aromatase inhibitor (AI) improved progression-free survival (PFS) versus single HER2 blockade in HER2-positive/hormone receptor (HR)-positive metastatic breast cancer.
  • Note that HER2–positive breast cancer (BC) constitutes approximately 20% to 25% of BC and is associated with poor prognosis,and approximately 50% of HER2-positive BCs are HR-positive, so HER2-positive/HR-positive represent roughly 10% of all BCs.

Targeting HER2 with two agents — lapatinib (Tykerb) and trastuzumab (Herceptin) — and adding an aromatase inhibitor (AI) significantly improved progression-free survival (PFS) compared to trastuzumab/AI in patients with HER2-positive and hormone receptor-positive metastatic breast cancer, researchers found.

Results from the large, randomized, phase III ALTERNATIVE trial demonstrated that the combination of lapatinib/trastuzumab/AI provided a clinically meaningful prolongation of PFS compared with trastuzumab/AI with a median PFS of 11.0 versus 5.7 months, respectively, according to Stephen R.D. Johnston, MA, PhD, of The Royal Marsden NHS Foundation Trust in London, and colleagues.

This represented a statistically significant 38% reduction in the risk of disease progression (hazard ratio [HR] 0.62; P=0.0064) in patients not suitable for chemotherapy, the study authors reported online in the Journal of Clinical Oncology. Lapatinib/trastuzumab/AI was also relatively well tolerated compared with trastuzumab/AI.

These findings indicate that patients with HER2-positive/HR-positive MBC who are not candidates for chemotherapy can be adequately treated with dual HER2 blockade plus an AI, Johnston and colleagues emphasized. “Although survival data were immature, there was also a trend in favor of the dual-blockade treatment (median 46.0 versus 40.0 months),” they wrote.

The PFS benefit of lapatinib/trastuzumab/AI compared with trastuzumab/AI was consistent across patient subgroups. The overall response rate (ORR) and clinical benefit rate (CBR) also favored the lapatinib/trastuzumab/AI combination over trastuzumab/AI (ORR 31.7% versus 13.7%, and CBR 41% versus 31%, respectively).

“Dual HER2 blockade enhances clinical benefit versus single HER2 blockade,” the study authors noted. “The use of dual anti-HER2 blockade represents a potential strategy to further improve the outcome of these patients,” Johnston and colleagues added.

The ALTERNATIVE trial enrolled 355 postmenopausal women from 112 sites in 29 countries. All patients had received prior endocrine therapy and experienced disease progression after prior neo(adjuvant)/first-line trastuzumab plus chemotherapy. Patients were randomly assigned 1:1:1 to lapatinib/trastuzumab/AI, trastuzumab/AI, or lapatinib/AI.

In the lapatinib/trastuzumab/AI arm, patients took 1,000 mg/day oral lapatinib. In the lapatinib/AI arm, patients took 1,500 mg/day. In both trastuzumab arms, patients received an IV loading dose of 8 mg/kg trastuzumab followed by a maintenance dose of 6 mg/kg every 3 weeks. Oral AIs included letrozole (Femara; 2.5 mg/day), antinuclear antibodies (1 mg/day), or exemestane (Aromasin; 25 mg/day).

The median PFS with lapatinib/AI versus trastuzumab/AI was 8.3 versus 5.7 months (HR 0.71; P=0.0361).

Common adverse events were seen in lapatinib/trastuzumab/AI; trastuzumab/AI; and lapatinib/AI, respectively, and included:

  • Diarrhea (69%, 9%, and 51%)
  • Rash (36%, 2%, and 28%)
  • Nausea (22%, 9%, and 22%)
  • Paronychia (30%, 0%, and 15%)

Frequency of adverse events, mostly grade 1 or 2, was 92% in the two lapatinib arms and 74% in the trastuzumab arm. Serious AEs were reported across the three study groups, with discontinuation lowest in the lapatinib/trastuzumab/AI arm (3%) compared to the trastuzumab/AI (6%) and lapatinib/AI (9%) arms.

Other studies looking at HER2 blockade have been conducted in different patient populations, so “cross-trial comparisons need to be interpreted with caution,” the study authors warned. Although the PFS outcome in ALTERNATIVE lines up with results from other studies, there are a limited number of trials designed for patients with HER2-positive/HR-positive metastatic breast cancer, they pointed out.

In the phase II PERTAIN study of locally advanced or metastatic hormone receptor-positive HER2-positive breast cancer patients, the addition of pertuzumab (Perjeta) to a regimen of trastuzumab and an AI in the first-line setting significantly improved PFS by 3 months. The median PFS was 18.9 months with pertuzumab, trastuzumab and endocrine therapy compared to 15.80 months with trastuzumab plus endocrine therapy.

However, only 77% of patients were trastuzumab-naive and 55% of patients had received induction chemotherapy in this first-line setting, the ALTERNATIVE study authors noted.

The rationale for PERTAIN came from the TAnDEM study, which showed that adding trastuzumab to anastrozole (Arimidex) significantly improved PFS over anastrozole alone. The CLEOPATRA study also demonstrated improved PFS and OS with the addition of pertuzumab to trastuzumab plus docetaxel.

These findings contrast the lack of benefit observed with lapatinib in the adjuvant setting in the Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization (ALTTO) trial, Johnston and colleagues pointed out. In addition, the APHINITY trial demonstrated only a modest benefit with pertuzumab.

“This discrepancy may be the result, at least in part, of the excellent outcome with adjuvant single HER2 blockade with TRAS, making the demonstration of additional benefit with dual blockade harder. Dual HER2 blockade may benefit only a small subset of high-risk patients,” they suggested.

Similarly, results from an earlier international trial showed that adjuvant therapy with two HER2-targeted drugs failed to improve disease-free survival in early breast cancer compared with trastuzumab monotherapy. Concurrent administration of lapatinib and trastuzumab resulted in a nonsignificant 16% reduction in DFS compared with trastuzumab alone.

However, in a nonrandomized phase II study, the combination of lapatinib and trastuzumab was effective and well-tolerated in patients with HER2+ breast cancer who had received up to two lines of therapy for advanced disease. The study also showed that metabolic imaging appeared to be helpful for selecting poor responders in advance, thus sparing them the toxicity of chemotherapy.

Original funding for the ALTERNATIVE study was provided by GlaxoSmithKline. As of March 2, 2015, lapatinib was acquired by Novartis, the current sponsor of this study. Johnston reported relationships with Novartis, Eli Lilly, AstraZeneca, OBI Pharma, Puma Biotechnology, and Pfizer. A number of study co-authors also reported relationships with industry, including GlaxoSmithKline and Novartis.

2017-12-28T14:30:00-0500

Tagged with:

About author

Related Articles